PTHS Pelthos Therapeutics Inc.

Price (delayed)

$23.52

Market cap

$90.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$27.57

Enterprise value

$138.59M

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 26
Relative Valuation: Rel. Valuation: 20
Relative Profitability: Rel. Profitability: 13

Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive, therapeutics to alleviate pain and other associated medical conditions. The Company’s initial clinical focus ...

Highlights
The revenue has soared by 56% from the previous quarter
The gross profit has surged by 54% since the previous quarter
The equity has dropped by 108% since the previous quarter but it has surged by 77% year-on-year
The EPS has dropped by 89% year-on-year and by 5% since the previous quarter
The quick ratio has declined by 31% since the previous quarter

Key stats

What are the main financial stats of PTHS

PTHS stock price

How has the Pelthos Therapeutics stock price performed over time
Intraday
1.2%
1 week
21.11%
1 month
-7.8%
1 year
-30.74%
YTD
-24.13%
QTD
-16.77%

Financial performance

How have Pelthos Therapeutics's revenue and profit performed over time
Revenue
$43.3M
Gross profit
$34.03M
Operating income
-$57.78M
Net income
-$86.39M
Gross margin
78.6%
Net margin
-199.5%
The revenue has soared by 56% from the previous quarter
The gross profit has surged by 54% since the previous quarter
PTHS's operating income is down by 32% since the previous quarter
PTHS's net income is down by 30% since the previous quarter

Price vs fundamentals

How does PTHS's price correlate with its fundamentals

Growth

What is Pelthos Therapeutics's growth rate over time

Valuation

What is Pelthos Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.2
The EPS has dropped by 89% year-on-year and by 5% since the previous quarter
The equity has dropped by 108% since the previous quarter but it has surged by 77% year-on-year
The stock's price to sales (P/S) is 62% less than its last 4 quarters average of 5.0
The revenue has soared by 56% from the previous quarter

Efficiency

How efficient is Pelthos Therapeutics business performance
The ROA has soared by 91% YoY and by 2.9% from the previous quarter
The return on equity has declined by 24% since the previous quarter
The return on invested capital rose by 19% since the previous quarter
The ROS is up by 19% since the previous quarter

Dividends

What is PTHS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PTHS.

Financial health

How did Pelthos Therapeutics financials performed over time
The quick ratio has declined by 31% since the previous quarter
Pelthos Therapeutics's current ratio has decreased by 29% QoQ
The equity has dropped by 108% since the previous quarter but it has surged by 77% year-on-year
The company's debt rose by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.